- Fusion Antibodies said its new antibody services platform has been launched at an industry conference in San Diego last week.

The service was designed to improve the affinity of therapeutic antibodies being developed by drug discovery companies.

It could improved efficacy of the treatment and the potential for lower dosages, reducing production costs for the manufacturer and perhaps improving tolerability in the patient, Fusion said.

The company said it had applied for patent protection for the platform, which would be offered to customers on a fee-for-service basis, with milestone success payments sought where appropriate.

The launch was not expected to generate significant revenues in the financial period ending March 2019, but was expected to contribute to growth in the following year.

At 2:39pm: [LON:FAB] Fusion Antibodies Plc Ord 4p share price was +2p at 54.5p

Story provided by